This study highlights SH3GL1 as a novel regulator of ferroptosis in DLBCL, suggesting that targeting SH3GL1 could be a promising strategy to prevent DLBCL progression and overcome doxorubicin resistance. The gene discussed is SH3GL1; the disease is diffuse large B-cell lymphoma.